Top 5 Takeaways for Gastrointestinal Cancer Management From 2025 ASCO GI
Data from 2025 ASCO GI support the potential role that combinations such as nivolumab/ipilimumab may play a part in managing different types of GI cancers.
Related Articles
🚨 The OncoAlert Colloquium Feb 2025
A 100% virtual, week-long meeting highlighting the most important developments in oncology each year, delivered by some of the world’s leading oncologists in a multidisciplinary…
Encorafenib/Cetuximab Plus Chemo Improves Survival in BRAF V600E+ mCRC
Encorafenib plus cetuximab and mFOLFOX6 improved PFS and OS vs chemotherapy in BRAF V600E–mutant metastatic colorectal cancer.
NSCLC Experts Ponder Best First-Line Treatment Options
The discussion on NSCLC narrowed in on findings from recent clinical trials, particularly involving a combination regimen of amivantamab plus lazertinib vs osimertinib and chemotherapy.
Managing Unseen Risks: Understanding Recurrence in Early Breast Cancer With No or Limited Nodal Involvement
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
TACE and Durvalumab/Bevacizumab in Unresectable HCC
“Durvalumab plus bevacizumab plus [transarterial chemoembolization (TACE)] has the potential to set a new standard of care” in this patient population, according to researchers who…
Early Detection of Ovarian Cancer Using Cell-Free DNA Fragmentomes and Protein Biomarkers
A genome-wide machine learning approach integrating cfDNA fragmentomes and biomarkers detected all stages of ovarian cancer with high sensitivity and specificity, and may enable new,…
The 5th Annual OncoAlert Colloquium
The Year in Review in Oncology 2024 brought to you by some of the Worlds TOP experts!
Targeting CD47: many misses; hopeful for a hit
In this issue of Blood, Ma et al describe the in vivo efficacy of a novel, bivalent CD47 immunotoxin used as targeted therapy for the treatment of…
FDA Approves Companion Diagnostic for T-DXd in HER2-Ultralow Metastatic Breast Cancer
The FDA has approved a companion diagnostic for trastuzumab deruxtecan in hormone receptor–positive, HER2-ultralow metastatic breast cancer.
Relapse-free survival is progressively shortened in a subset of Black patients with immune-mediated TTP treated in the rituximab era
Key PointsRFS shortens with successive rituximab-treated episodes in a subgroup of relapsing patients with iTTP.Progressively shortened time to relapse is
